Group A streptococcal sepsis

Current Infectious Disease Reports

Volumn 5, Issue 5, 2003, Pages 379-386

  Stevens, Dennis L ^a  

^a Boise VA Medical Center   (United States)

Author keywords

Clindamycin; Invasive Group; Necrotizing Fasciitis; Scarlet Fever; Streptococcal Infection

Indexed keywords

EID: 1642320919     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-003-0017-7     Document Type: Article

References (53)

1. The Working Group on Severe Streptococcal Infections: Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA 1993, 269:390–391.
2. Schwartz B, Facklam RR, Brieman RF: Changing epidemiology of group A streptococcal infection in the USA. Lancet 1990, 336:1167–1171.
3. Cockerill FR, MacDonald KL, Thompson RL, et al.: An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA 1997, 277:38–43.
4. Outbreak of group A streptococcal pneumonia among Marine Corps recruits--California, November 1-December 20, 2002. MMWR Morb Mortal Wkly Rep 2003, 52:106–109.
5. Chaussee MS, Liu J, Stevens DL, Ferretti JJ: Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. J Infect Dis 1996, 173:901–908.
6. Gamba MA, Martinelli M, Schaad HJ, et al.: Familial transmission of a serious disease-producing group A streptococcus clone: case reports and review. Clin Infect Dis 1997, 24:1118–1121.
7. Dipersio JR, File TM, Stevens DL, et al.: Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. Clin Infect Dis 1996, 22:490–495.
8. Ichiyama S, Nakashima K, Shimokata K, et al.: Transmission of Streptococcus pyogenes causing toxic shock-like syndrome among family members and confirmation by DNA macrorestriction analysis. J Infect Dis 1997, 175:7231–7236.
9. Gamba MA, Martinelli M, Schaad HJ, et al.: Familial transmission of a serious disease-producing group A streptococcus clone: case reports and review. Clin Infect Dis 1997, 24:1118–1121.
10. Dipersio JR, File TM, Stevens DL, et al.: Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. Clin Infect Dis 1996, 22:490–495.
11. Auerbach SB, Schwartz B, Williams D, et al.: Outbreak of invasive group A streptococcal infections in a nursing home. Lessons on prevention and control. Arch Intern Med 1992, 152:1017–1022.
12. Hohenboken JJ, Anderson F, Kaplan EL: Invasive group A streptococcal (GAS) serotype M-1 outbreak in a long-term care facility (LTCF) with mortality. In Program & Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL. 1994:Abstract J189.
13. Nosocomial group A streptococcal infections associated with asymptomatic health-care workers--Maryland and California, 1997. MMWR Morb Mortal Wkly Rep 1999, 48:163–166.
14. Stevens DL, Tanner MH, Winship J, et al.: Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West: severe group A streptococcal infections associated with a toxic shock-like syndrome. N Eng J Med 1989, 321:1–7.
15. Bisno AL, Stevens DL: Streptococcal infections in skin and soft tissues. N Engl J Med 1996, 334:240–245.
16. Demers B, Simor AE, Vellend H, et al.: Severe invasive group A streptococcal infections in Ontario, Canada: 1987–1991. Clin Infect Dis 1993, 16:792–800.
17. Stegmayr B, Bjorck S, Holm S, et al.: Septic shock induced by group A streptococcal infections: clinical and therapeutic aspects. Scand J Infect Dis 1992, 24:589–597.
18. Kim KS, Kaplan EL: Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. J Pediatr 1985, 107:681–684.
19. Gatanaduy AS, Kaplan EL, Huwe BB, et al.: Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis. Lancet 1980, 2:498–502.
20. Brook I: Role of beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococci. Pediatr Infect Dis 1985, 4:491–495.
21. Adams EM, Gudmundsson S, Yocum DE, et al.: Streptococcal myositis. Arch Intern Med 1985, 145:1020–1023.
22. Stevens DL: Invasive group A streptococcus infections. Clin Infect Dis 1992, 14:2–13.
23. Martin PR, Hoiby EA: Streptococcal serogroup A epidemic in Norway 1987–1988. Scand J Infect Dis 1990, 22:421–429.
24. Kohler W: Streptococcal toxic shock syndrome. Zentralbl Bakteriol 1990, 272:257–264.
25. Hribalova V: Streptococcus pyogenes and the toxic shock syndrome. Ann Intern Med 1988, 108:772.
26. Gaworzewska ET, Coleman G: Correspondence: group A streptococcal infections and a toxic shock-like syndrome. N Engl J Med 1989, 321:1546.
27. Eagle H: Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952, 13:389–399.
28. Stevens DL, Bryant-Gibbons AE, Bergstrom R, Winn V: The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988, 158:23–28.
29. Stevens DL, Bryant AE, Yan S: Invasive group A streptococcal infection: new concepts in antibiotic treatment. Int J Antimicrob Agents 1994, 4:297–301.
30. Stevens DL, Yan S, Bryant AE: Penicillin binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993, 167:1401–1405.
31. Yan S, Mendelman PM, Stevens DL: The in vitro antibacterial activity of ceftriaxone against Streptococcus pyogenes is unrelated to penicillin-binding protein 4. FEMS Microbiol Lett 1993, 110:313–318.
32. Yan S, Bohach GA, Stevens DL: Persistent acylation of highmolecular weight penicillin binding proteins by penicillin induces the post antibiotic effect in Streptococcus pyogenes. J Infect Dis 1994, 170:609–614.
33. Stevens DL, Maier KA, Mitten JE: Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother 1987, 31:213–218.
34. Gemmell CG, Peterson PK, Schmeling D, et al.: Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981, 67:1249–1256.
35. Stevens DL, Bryant AE, Hackett SP: Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis 1995, 20:S154-S157.
36. Zimbelman J, Palmer A, Todd J: Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999, 18:1096–1100.
37. Stevens DL, Madaras-Kelly KJ, Richards DM: In vitro antimicrobial effects of various combinations of penicillin and clindamycin against four strains of Streptococcus pyogenes. Antimicrob Agents Chemother 1998, 42:1266–1268.
38. Cruz K, Hollenberg S: Update on septic shock: the latest approaches to treatment. J Crit Illn 2003, 18:162–168. This is a current, concise review regarding the management of septic shock in patients in the intensive care unit.
39. Fisher CJ, Horowitz BZ, Albertson TE: Cardiorespiratory failure in toxic shock syndrome: effect of dobutamine. Crit Care Med 1985, 13:160–165.
40. Kaul R, McGeer A, Norrby-Teglund A, et al.: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. Clin Infect Dis 1999, 28:800–807.
41. Barry W, Hudgins L, Donta S, Pesanti E: Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992, 267:3315–3316.
42. Yong JM: Necrotising fasciitis. Lancet 1994, 343:1427.
43. Sriskandan S, Moyes D, Buttery LK, et al.: Streptococcal pyrogenic exotoxin A release, distribution, and role in a murine model of fasciitis and multiorgan failure due to Streptococcus pyogenes. J Infect Dis 1996, 173:1399–1407.
44. Miwa K, Fukuyama M, Ida N, et al.: Preparation of a superantigen-adsorbing device and its superantigen removal efficacies in vitro and in vivo. Int J Infect Dis 2003, 7:21–28. The authors of this paper developed a polystyrene-based device that absorbed more than 70% of staphylococcal and streptococcal superantigens from human plasma and reduced the available levels of TNF-_ and interleukin-8 from superantigen-stimulated whole blood. Extracorporeal blood purification through this device in superantigen-treated animals resulted in significant improvement in survival.
45. Stevens DL, Bryant AE, Hackett SP, et al.: Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. J Infect Dis 1996, 173:619–626.
46. Schwartz B, Elliot JA, Butler JC, et al.: Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. Clin Infect Dis 1992, 15:277–284.
47. Valenzuela TD, Hooton TM, Kaplan EL, Schlievert PM: Transmission of ’toxic strep’ syndrome from an infected child to a firefighter during CPR. Ann Emerg Med 1991, 20:90–92.
48. Stamm WE, Feeley JC, Facklam RR: Wound infections due to group A streptococcus traced to a vaginal carrier. J Infect Dis 1978, 138:287–292.
49. Davies HD, McGeer A, Schwartz B, et al.: Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996, 335:547–554.
50. Prevention of invasive group A streptococcal diseases among household contacts of case-patients: is prophylaxis warranted? The Working Group on Prevention of Invasive Group A Streptococcal Infections. JAMA 1998, 279:1206–1210.
51. Liu VC, Stevenson JG, Smith AL: Group A streptococcus mural endocarditis. Pediatr Infect Dis J 1992, 11:1060–1062.
52. Batzloff MR, Hayman WA, Davies MR, et al.: Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003, 187:1598–1608. This paper represents a novel approach to vaccine development. A 12-amino acid peptide from the C-repeat (ie, conserved) region of M protein was conjugated to diphtheria toxin. Active immunization elicited opsonic antibody against several different M-types and was protective against challenge with an M-6 strain of GAS.
53. Guzman CA, Talay SR, Molinari G, et al.: Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. J Infect Dis 1999, 179:901–906.